Literature DB >> 2164381

Ischemic heart disease risk in postmenopausal women. Effects of estrogen use on glucose and insulin levels.

E Barrett-Connor1, M Laakso.   

Abstract

We report the fasting and post-challenge plasma insulin and glucose levels in 469 nondiabetic postmenopausal women from the Rancho Bernardo cohort according to the current use of estrogen replacement therapy. In these older women, the use of noncontraceptive estrogen was not associated with impaired glucose tolerance. Estrogen-treated women had lower levels of insulin than women who were not taking estrogen; these differences were not explained by age, obesity, or differential hormone use by women with known glucose intolerance. There were no significant differences in glucose and insulin levels in those taking conjugated equine estrogen (Premarin) alone compared to those taking it with medroxyprogesterone acetate (Provera).

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2164381     DOI: 10.1161/01.atv.10.4.531

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  4 in total

Review 1.  Hormone replacement therapy in postmenopausal women with diabetes mellitus: a risk-benefit assessment.

Authors:  B Andersson
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

2.  Effect of oestrogen plus progestin on the incidence of diabetes in postmenopausal women: results from the Women's Health Initiative Hormone Trial.

Authors:  K L Margolis; D E Bonds; R J Rodabough; L Tinker; L S Phillips; C Allen; T Bassford; G Burke; J Torrens; B V Howard
Journal:  Diabetologia       Date:  2004-07-14       Impact factor: 10.122

3.  Fibrinolytic potential is significantly increased by oestrogen treatment in postmenopausal women with mild dyslipidaemia.

Authors:  O C Gebara; M A Mittleman; B W Walsh; I Lipinska; F K Welty; G Bellotti; J E Muller; F K Sacks; G H Tofler
Journal:  Heart       Date:  1998-09       Impact factor: 5.994

4.  The effect of gonadectomy and estradiol on sensitivity to oxidative stress.

Authors:  Alex F Bokov; Daijin Ko; Arlan Richardson
Journal:  Endocr Res       Date:  2009       Impact factor: 1.720

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.